دورية أكاديمية
Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
| العنوان: | Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy |
|---|---|
| المؤلفون: | Vishal Shah, Andrea McNatty, Lacey Simpson, Henry Ofori, Farah Raheem |
| المصدر: | Biomedicines, Vol 11, Iss 3, p 950 (2023) |
| بيانات النشر: | MDPI AG, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Biology (General) |
| مصطلحات موضوعية: | amivantamab-vmjw, lung cancer, EGFR, exon 20, NSCLC, Biology (General), QH301-705.5 |
| الوصف: | Objective: This study is a comprehensive review of the clinical pharmacology, pharmacokinetics, efficacy, safety, and clinical applicability of amivantamab-vmjw for metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutation. Data Synthesis: The literature search to identify clinical trials returned only the CHRYSALIS phase 1 study. In a phase I trial, amivantamab-vmjw was associated with an overall response rate (ORR) of 40% (95% CI, 29–51) in the EGFR exon20ins NSCLC patient population (n = 81) after platinum-based chemotherapy. There were 3 complete responses (CRs) and 29 partial responses (PRs). The median duration of response (DOR) was 11.1 months (95% CI, 6.9—not reached; NR). The median progression-free survival (PFS) was 8.3 months (95% CI, 6.5–10.9), and overall survival (OS) was 22.8 months (95% CI, 14.6—NR). Application to Clinical Practice: This review summarizes the pharmacology, clinical evidence, and use of amivantamab-vmjw for patients with locally advanced or metastatic NSCLC with EGFR exon20ins mutation. Conclusion: The FDA approval of amivantamab-vmjw, the first bispecific antibody to target the exon20ins mutation, represents an important advancement in the treatment of patients with NSCLC with limited effective treatment options. The initial findings of the CHRYSALIS trial demonstrate an overall tumor response benefit with an acceptable safety profile. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2227-9059 |
| العلاقة: | https://www.mdpi.com/2227-9059/11/3/950Test; https://doaj.org/toc/2227-9059Test |
| DOI: | 10.3390/biomedicines11030950 |
| الوصول الحر: | https://doaj.org/article/e0ad725d81794bc4a3d167d04f151a29Test |
| رقم الانضمام: | edsdoj.0ad725d81794bc4a3d167d04f151a29 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsdoj Directory of Open Access Journals edsdoj.0ad725d81794bc4a3d167d04f151a29 958 3 Academic Journal academicJournal 958.050231933594 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.0ad725d81794bc4a3d167d04f151a29&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doaj.org/article/e0ad725d81794bc4a3d167d04f151a29 [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=22279059&ISBN=&volume=11&issue=3&date=20230301&spage=950&pages=950-950&title=Biomedicines&atitle=Amivantamab-Vmjw%3A%20A%20Novel%20Treatment%20for%20Patients%20with%20NSCLC%20Harboring%20EGFR%20Exon%2020%20Insertion%20Mutation%20after%20Progression%20on%20Platinum-Based%20Chemotherapy&id=DOI:10.3390/biomedicines11030950 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Vishal+Shah%22">Vishal Shah</searchLink><br /><searchLink fieldCode="AR" term="%22Andrea+McNatty%22">Andrea McNatty</searchLink><br /><searchLink fieldCode="AR" term="%22Lacey+Simpson%22">Lacey Simpson</searchLink><br /><searchLink fieldCode="AR" term="%22Henry+Ofori%22">Henry Ofori</searchLink><br /><searchLink fieldCode="AR" term="%22Farah+Raheem%22">Farah Raheem</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Biomedicines, Vol 11, Iss 3, p 950 (2023) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => MDPI AG, 2023. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2023 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Biology (General) ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22amivantamab-vmjw%22">amivantamab-vmjw</searchLink><br /><searchLink fieldCode="DE" term="%22lung+cancer%22">lung cancer</searchLink><br /><searchLink fieldCode="DE" term="%22EGFR%22">EGFR</searchLink><br /><searchLink fieldCode="DE" term="%22exon+20%22">exon 20</searchLink><br /><searchLink fieldCode="DE" term="%22NSCLC%22">NSCLC</searchLink><br /><searchLink fieldCode="DE" term="%22Biology+%28General%29%22">Biology (General)</searchLink><br /><searchLink fieldCode="DE" term="%22QH301-705%2E5%22">QH301-705.5</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Objective: This study is a comprehensive review of the clinical pharmacology, pharmacokinetics, efficacy, safety, and clinical applicability of amivantamab-vmjw for metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutation. Data Synthesis: The literature search to identify clinical trials returned only the CHRYSALIS phase 1 study. In a phase I trial, amivantamab-vmjw was associated with an overall response rate (ORR) of 40% (95% CI, 29–51) in the EGFR exon20ins NSCLC patient population (n = 81) after platinum-based chemotherapy. There were 3 complete responses (CRs) and 29 partial responses (PRs). The median duration of response (DOR) was 11.1 months (95% CI, 6.9—not reached; NR). The median progression-free survival (PFS) was 8.3 months (95% CI, 6.5–10.9), and overall survival (OS) was 22.8 months (95% CI, 14.6—NR). Application to Clinical Practice: This review summarizes the pharmacology, clinical evidence, and use of amivantamab-vmjw for patients with locally advanced or metastatic NSCLC with EGFR exon20ins mutation. Conclusion: The FDA approval of amivantamab-vmjw, the first bispecific antibody to target the exon20ins mutation, represents an important advancement in the treatment of patients with NSCLC with limited effective treatment options. The initial findings of the CHRYSALIS trial demonstrate an overall tumor response benefit with an acceptable safety profile. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2227-9059 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://www.mdpi.com/2227-9059/11/3/950; https://doaj.org/toc/2227-9059 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.3390/biomedicines11030950 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/e0ad725d81794bc4a3d167d04f151a29" linkWindow="_blank">https://doaj.org/article/e0ad725d81794bc4a3d167d04f151a29</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.0ad725d81794bc4a3d167d04f151a29 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.3390/biomedicines11030950
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 1
[StartPage] => 950
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => amivantamab-vmjw
[Type] => general
)
[1] => Array
(
[SubjectFull] => lung cancer
[Type] => general
)
[2] => Array
(
[SubjectFull] => EGFR
[Type] => general
)
[3] => Array
(
[SubjectFull] => exon 20
[Type] => general
)
[4] => Array
(
[SubjectFull] => NSCLC
[Type] => general
)
[5] => Array
(
[SubjectFull] => Biology (General)
[Type] => general
)
[6] => Array
(
[SubjectFull] => QH301-705.5
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Vishal Shah
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Andrea McNatty
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lacey Simpson
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Henry Ofori
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Farah Raheem
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 03
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 22279059
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 11
)
[1] => Array
(
[Type] => issue
[Value] => 3
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Biomedicines
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |